Neuropathy clinic marketing: reverse and regrow claims, cleared devices, seminar dinners and 911 wording

A neuropathy clinic speaks to people who have lived with burning, tingling or numb feet for months or years, who may have been told there is little more to do, and who are searching for something that works. The clinic may sit inside a neurology group, a podiatry practice, a pain practice, a primary care office or a multi-disciplinary clinic that also offers physical therapy or chiropractic care. This guide covers what the federal sources say about peripheral neuropathy, the emergency and foot wound wording each page and tool needs, how to write about reversing or regrowing nerves without promising it, how to describe devices that FDA has cleared, dinner seminars, and money from equipment suppliers.

Eight related topics have their own guides and are not repeated here. Pain treatment pages and controlled substances are covered in our guide to pain management clinic marketing, and diabetic foot care and the Medicare foot exam benefit in our guide to podiatry practice marketing. Writing for patients referred to a neurologist is covered in our guide to neurology practice marketing, and the full rules on device wording in our guide to medical device marketing claims. Event rules, meals and Medicare attendees are covered in our guide to patient education seminars, and braces, shoes and other equipment in our guide to DME supplier marketing. Diabetes classes are covered in our guide to diabetes education program marketing, and supplements sold in the office in our guide to selling supplements in a medical practice.

What NINDS, NIDDK and MedlinePlus say

The National Institute of Neurological Disorders and Stroke (NINDS) leads federal research on nerve disorders, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) publishes the federal pages on diabetes-related nerve damage, and MedlinePlus from the National Library of Medicine publishes the federal patient pages. The points that shape a clinic’s marketing:

• The NINDS Peripheral Neuropathy page (last reviewed on March 13, 2026) says more than 100 types of peripheral neuropathy have been identified, each with its own symptoms and likely course, and that diabetes is the leading cause of peripheral neuropathy in the U.S. It lists other causes, including injury, autoimmune disease, kidney and liver disorders, vitamin imbalances, alcohol, toxins, infections, cancer and some medicines, including chemotherapy.
• The same page says treatment depends on the type and location of nerve damage and the person’s symptoms, that when the underlying cause is corrected the neuropathy can in some cases resolve on its own as nerves recover and regrow, and that managing diabetes may help reduce or eliminate the symptoms of diabetic neuropathy. It tells readers to talk with a doctor before stopping any medicine.
• NINDS also says neuropathies that involve scattered nerve damage are not helped by surgery, and that the only neuropathy treated with surgery is carpal tunnel syndrome. It describes medicines, nerve stimulation, braces and shoes, and complementary approaches such as acupuncture, massage and tai chi as ways that may help people manage symptoms.
• The MedlinePlus encyclopedia article Peripheral neuropathy (review date May 4, 2026) says how well a person does depends on the cause and duration of nerve damage, that the outlook may be excellent when a medical condition can be found and treated, that nerve damage can in some cases be permanent even if the cause is treated, and that there is no cure for a majority of the neuropathies passed down in families.
• The NIDDK Peripheral Neuropathy page (last reviewed February 2018, older than two years) says up to one-half of people with diabetes have peripheral neuropathy, that lost feeling in the feet can lead to sores and infections and to the loss of a toe, foot or part of the leg, and that people with diabetes should have a foot exam at least once a year. It says diabetes experts have not made special recommendations about supplements for people with diabetes.
• The MedlinePlus Peripheral Nerve Disorders page (last updated June 27, 2024) says damaged nerves may not carry messages correctly or may not work at all, and lists a lack of vitamin B12 among the causes.

Two points shape the marketing. First, neuropathy is a group of conditions with different causes, so a page that promises one answer for all of them says more than any source here. Second, the federal sources do say nerves can recover in some cases, which makes it tempting to write “reverse your neuropathy” as a headline. NINDS ties recovery to finding and correcting the cause, and MedlinePlus says the damage can be permanent. A page can explain both sides without a promise.

Reverse, regrow and “no drugs, no surgery” claims

Google’s search suggestions, which we checked on October 30, 2026, offer “can neuropathy be reversed or cured”, “can neuropathy be reversed in feet”, “can neuropathy be reversed naturally” and “can neuropathy be reversed if caught early” to a person who starts typing “can neuropathy be reversed”, and “neuropathy treatment for feet at home” after “neuropathy treatment”. A clinic page can answer that question honestly: quote NINDS on recovery when the cause is corrected, quote MedlinePlus on permanent damage, and say the clinician first looks for the cause, with the history, exam and tests NINDS describes, before discussing treatment.

Phrases that need rewriting:

• “Reverse your neuropathy without drugs or surgery.” A results promise. NINDS ties recovery to the cause, and MedlinePlus says damage can be permanent. Remove it.
• “Regrow your nerves in 12 weeks.” A timed results claim with no source behind it. Remove it.
• “Our breakthrough protocol works for all types of neuropathy.” NINDS says there are more than 100 types and that treatment depends on the type. Remove it.
• “Stop your pain medicines for good.” NINDS tells readers to talk with a doctor before stopping any medicine. Remove it, and say the clinician reviews medicines with the patient.
• “Avoid amputation with our program.” Fear plus a promise. Describe foot exams and wound care in the NIDDK terms instead.
• “Doctors told you nothing can be done? They were wrong.” Disparages other clinicians and implies a result. Remove it.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. “Walk without pain again” is a health benefit claim even without a number.

Emergency signs and 911 on every page and in every tool

Two kinds of urgent messages reach a neuropathy clinic. The first is fast weakness. The MedlinePlus encyclopedia article Guillain-Barre syndrome (review date April 16, 2025) lists emergency symptoms that need medical help right away, including being unable to take a deep breath, difficulty breathing, difficulty swallowing or choking, drooling, fainting and feeling light headed when standing, and the NINDS Guillain-Barré Syndrome page (last reviewed on March 13, 2026) says the disorder can be life-threatening when it affects breathing, blood pressure or heart rate. Put a short line above the booking button: if you have trouble breathing or swallowing, or weakness that is spreading quickly, call 911.

The second is the foot. The MedlinePlus encyclopedia article Diabetes, taking care of your feet (review date May 18, 2026) tells people with diabetes to contact their provider right away about foot problems, such as redness, warmth, swelling, sores or cracks, and not to treat these problems themselves. A page can say who answers the clinic’s number and when, and how a patient with a new sore gets seen. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Phrases that need rewriting:

• “Sudden weakness in your legs? Book a free consultation.” Put the 911 line first, and the booking form after it.
• “Treat foot sores at home with our kit.” MedlinePlus says not to treat these problems yourself. Remove it.
• “Message us any time.” Say who reads messages, during which hours, that the inbox is not watched around the clock, and give 911 for emergencies.

Devices: cleared is not approved

Neuropathy clinics market light, laser, electrical stimulation, vibration and other devices. The FDA page Premarket Notification 510(k) (content current as of August 22, 2024) says a 510(k) shows that a device is substantially equivalent to a legally marketed device, and that FDA’s order finding it so “clears” the device for commercial distribution. Clearance is not approval, and the regulation says so directly: under 21 CFR 807.97, any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding.

Two more limits apply. A device is cleared for a stated intended use, and a page that markets it for something else, for example regrowing nerves when it was cleared only for temporary pain relief, makes a claim the clearance does not cover. And a clearance is about the device, not the clinic’s results. Ask the manufacturer for the clearance letter and the indications for use, quote them, and name no brand on the page. Our guide to medical device marketing claims covers intended use and FTC review in full.

Phrases that need rewriting:

• “FDA-approved neuropathy laser.” Wrong word for a 510(k) device and misleading under 21 CFR 807.97. Say the device is FDA cleared for the use stated in its clearance, if that is true.
• “FDA cleared to reverse neuropathy.” Check the indications for use; a clearance for temporary pain relief does not cover nerve repair. Quote the cleared use.
• “Our exclusive device, the only one of its kind.” A comparison claim with no data. Describe the device type and what it is cleared for.

Supplements, injections and other add-ons

Some neuropathy programs bundle vitamins, supplements or injections with device sessions. NINDS lists vitamin B12 deficiency and excess vitamin B6 as the best-known vitamin-related causes of neuropathy, and NIDDK says a doctor may test for low B12 to rule out other causes. That supports testing, not a supplement pitch. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed, and NIDDK says to talk with a doctor before using supplements. Name no product, give no doses, and follow our guide to selling supplements in a medical practice if the clinic sells them. Our guide to stem cell clinic advertising covers regenerative injection claims.

Phrases that need rewriting:

• “Our nerve vitamin formula repairs damaged nerves.” A disease claim for a supplement with no source here. Remove it.
• “More B6 means healthier nerves.” NINDS lists excess B6 as a cause of neuropathy. Remove it.
• “Regenerative injections rebuild nerve tissue.” A results claim; see the stem cell guide before any injection page goes live.

Seminar dinners and free offers

The free dinner seminar is a familiar neuropathy channel. Our guide to patient education seminars covers meals, Medicare attendees and what the speaker says, and its rules apply here. Two points matter for neuropathy in particular. A “free” meal, exam or nerve test follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and the terms of the offer should be stated at the outset. And the invitation is an ad: “Learn how to reverse neuropathy” makes the same claim on a postcard that it makes on a website.

Package prices for a course of device sessions belong on the page in plain terms, with what is included and the refund terms. Our guides to advertising cash prices and good faith estimates for self-pay patients cover how to state a price and what uninsured and self-pay patients must receive. Say how the clinic checks coverage, and do not say a program “is covered” before it has been checked for the patient’s plan.

Phrases that need rewriting:

• “Free steak dinner: learn the secret doctors won’t tell you.” A secret-cure frame and an attack on other clinicians. Describe the talk’s topics and the speaker’s license.
• “Free nerve test tonight only, sign up for the program at the door.” Pressure plus a free offer tied to a sale. State the terms at the outset and give time to decide.
• “Medicare covers our program.” Coverage depends on the service and the patient. Say the clinic checks coverage before treatment.

Referrals, equipment suppliers and sponsors

Neuropathy clinics draw partners: podiatrists and primary care offices, equipment and shoe suppliers, device makers with financing or marketing programs, labs, compounding pharmacies and supplement makers. Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state. Our guide to patient and physician referrals covers the general rules.

For a neuropathy clinic, keep these points:

• Do not take payments, free staff or marketing help from a brace, shoe or equipment supplier in return for orders without counsel’s review. Our guide to DME supplier marketing covers the supplier side.
• Device maker marketing kits, co-op ad money and seminar scripts go to counsel before use, and the clinic edits the claims in them to match this guide.
• Do not give gifts, meals or payments to referring offices in return for patients without counsel’s review. Payments to physicians from manufacturers may be reported publicly; our guide to Open Payments covers that.
• Clinics that see Medicaid patients follow the rules in our guide to marketing to Medicaid patients.

Privacy, pixels and ads

A visit to a neuropathy page, a seminar sign-up or a symptom quiz says something about a person’s health, and a quiz that asks about diabetes or foot sores says more. Keep sign-ups, quiz answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with diabetes or neuropathy.

Under 45 CFR 164.501, a reminder about the practice’s own treatment for an individual, such as a foot exam or a follow-up visit, can fall outside the definition of marketing, while a message that promotes a third party’s product, such as a supplier’s shoes or a supplement, generally needs a signed authorization under 45 CFR 164.508. Reminder texts name no condition, no result and no product in the message text.

Patient stories

A patient who describes sleeping through the night again, or a spouse who explains what the first visit was like, can help someone facing the same thing. It is still one person’s experience, and in neuropathy the cause differs from patient to patient. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. “I threw away my cane after six sessions” is a results claim. Keep stories to the experience of care and the team.

Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, and consent for any photo or video. Name no device brand, medicine or supplement, say if the patient received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two neuropathy clinic pages

Illustration: a page reads “Reverse your neuropathy without drugs or surgery. Our FDA-approved laser regrows nerves in 12 weeks, and our nerve vitamin formula speeds healing. Free steak dinner Thursday: learn the secret your doctor won’t tell you. Leg weakness getting worse? Book your free consultation.” It promises recovery the sources tie to the cause, calls a cleared device approved, makes a disease claim for a supplement, frames a dinner as a secret, and puts a booking link where the 911 line belongs.

Illustration: a second page for the same practice reads “If you have trouble breathing or swallowing, or weakness that is spreading quickly, call 911. At [Practice name], [Clinician name, license] starts by looking for the cause of your symptoms, with a history, an exam and tests where they fit. Some neuropathy improves when the cause is treated, and some nerve damage is permanent; we explain what we find and the options, including devices FDA has cleared for the uses stated in their clearances. People with diabetes who notice a new foot sore should call us right away at [phone] during [days and hours].” It puts the emergency line first, quotes what the sources say, and promises nothing it cannot show.

Checklist before a neuropathy clinic campaign goes live

• NINDS, NIDDK and MedlinePlus pages named and dated, with pages older than two years marked as older and checked against newer sources at each review.
• The 911 line for breathing, swallowing and fast-spreading weakness above any booking button, and in voicemail, portal replies, text replies, chat and AI front desk tools.
• Foot sore wording that sends patients with diabetes to the clinic right away and warns against treating sores at home.
• No reverse, regrow, heal or end-your-pain promises; recovery described in the NINDS terms, tied to the cause, with the MedlinePlus line on permanent damage.
• Devices described as FDA cleared only where true and only for the cleared use; no “FDA approved” for a 510(k) device, no brand names.
• No supplement disease claims, no doses, no product names; supplement sales follow the supplements guide.
• Seminar invitations carry no cure or secret claims; free meals and tests follow 16 CFR 251.1 and the seminar guide.
• Package prices, what they include and refund terms stated; coverage stated as checked.
• No payments or free help from suppliers or device makers tied to orders or referrals without counsel’s review.
• Quiz answers, sign-ups and bookings stay out of pixels and ad audiences; targeting by place and search terms only.
• Stories have signed authorizations, name no product, make no results claim and carry a statement of what patients can generally expect.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including neurology, podiatry and pain practices that run neuropathy programs. For a neuropathy clinic, that means a site that quotes NINDS, NIDDK and MedlinePlus as written and dated, puts the 911 line above the booking button, answers “can neuropathy be reversed” searches without a promise, and describes devices in their cleared terms, plus booking and seminar sign-up pages that keep answers off the web and away from tracking tools. Our front desk tools hand urgent messages to the 911 line and the on-call number, and do not triage symptoms. We do not decide who needs treatment; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NINDS: Peripheral Neuropathy (last reviewed on March 13, 2026)
• NINDS: Guillain-Barré Syndrome (last reviewed on March 13, 2026)
• NIDDK: Peripheral Neuropathy (last reviewed February 2018)
• MedlinePlus: Peripheral Nerve Disorders (last updated June 27, 2024)
• MedlinePlus encyclopedia: Peripheral neuropathy (review date May 4, 2026)
• MedlinePlus encyclopedia: Guillain-Barre syndrome (review date April 16, 2025)
• MedlinePlus encyclopedia: Diabetes, taking care of your feet (review date May 18, 2026)
• FDA: Premarket Notification 510(k) (content current as of August 22, 2024)
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing